I et humant 14C - tipranavir- forsøg (14C- tipranavir/ ritonavir, 500 mg/ 200 mg to gange daglig) udgjorde uforbundet tipranavir 98, 4% eller mere af den totale cirkulerende plasmaradioaktivitet, 3, 8 eller 12 timer efter dosering.
In a 14C-tipranavir human study (14C-tipranavir/ ritonavir, 500 mg/ 200 mg twice daily), unchanged tipranavir was predominant and accounted for 98.4% or greater of the total plasma radioactivity circulating at 3, 8, or